Astrocyte Pharmaceuticals Announces Theodore Liston, Ph.D., Vice President of Research, as Recipient of the 2022 Innovation and Progress Award from the Journal Stroke.
Currently, there are no gene editing–based treatments on the market, but the technology continues its march toward potential FDA approval, with several products in mid- and late-stage trials.
Gene Editing Therapeutics Could Hit the Market in 2023 Read More »
Evecxia Therapeutics, Inc. today announced favorable safety, tolerability, pharmacokinetic, and pharmacodynamic data from a double-blind, placebo-controlled Phase 1, a two-part single ascending dose (SAD) and multiple ascending dose (MAD) trial of EVX-101 in healthy volunteers treated with escitalopram.
Aviceda is partnering with world-renowned scientist Professor Christopher Scott and his teams at the Patrick G. Johnson Centre for Cancer Research at Queen’s University Belfast to spearhead development of the next generation of glyco-immune therapeutics.
Virginia Commonwealth University’s Stravitz-Sanyal Institute for Liver Disease and Metabolic Health has announced a partnership with Singapore -headquartered medtech company, Histoindex Pte Ltd.
Can-Fite BioPharma Ltd today announced that it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) with respect to the submission of a registration plan for a pivotal Phase III clinical trial for the treatment of moderate to severe psoriasis.
Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that the company plans to release its first quarter 2023 financial results after the close of the U.S. financial markets on May 9, 2023.
Exact Sciences schedules first quarter 2023 earnings call Read More »
Theravance Biopharma, Inc. will present at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17 at 3:45 pm ET.
Theravance Biopharma to Participate in an Upcoming April 2023 Investor Conference Read More »
OBI Pharma, Inc. announced preclinical data demonstrating significant synergistic effects of OBI-999 and pembrolizumab in four different cancer models, as well as the potent antitumor effect of a chimeric antigen receptor T-cell immunotherapy targeting Globo H.
Mainz Biomed N.V. announced financial results for the fiscal year ended December 31, 2022.
Mainz Biomed Provides Full Year 2022 Financial Results Read More »
